NERV Share Price Performance
US$2.18
-0.47 (-17.74%)
Price US$2.18
Share PriceUS$2.18
Minerva Neurosciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
NERV Community Narratives
There are no narratives available yet.
Recent NERV News & Updates
Minerva Neurosciences, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 1.61
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -186.9%
Minerva Neurosciences, Inc. Competitors
Snowflake Analysis
About NERV
- Founded
- 2007
- Employees
- 8
- CEO
- WebsiteView website
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 1.1%
- 3 Months: 8.9%
- 1 Year: 18.9%
- Year to Date: 15.1%
Over the last 7 days, the market has risen 1.1%, driven by gains of 1.9% in the Information Technology sector. The market is up 19% over the last 12 months. Earnings are forecast to grow by 15% annually. Market details ›